ARCH Venture Partners

Venture capital firm
Chicago, IL

Strategy

Stages
SeedSeries ASeries B
Sectors
BiotechHealthcareDeeptech
Geographies
USAChicago, IL
Check size
$1M-$50M

Portfolio

3 total

Sector / Stage Activity

By sector (portfolio)
Biotech
2 · 67%
Quantum computing
1 · 33%

Co-Investors

12

Latest Pulse

Pulse coverage →
  1. Ollin Biosciences Raises $330M Series B to Advance Its Therapeutics PipelineOllin Biosciences raised a $330 million Series B co-led by TCG Crossover and Arch Venture Partners, one of the largest life-sciences rounds of the week. The financing pushes its therapeutics pipeline deeper into clinical development and adds to mounting evidence that biotech's capital markets have reopened in force alongside the AI boom.
  2. Ollin Biosciences Raises $330M Series B for Next-Generation Eye Disease TherapiesOllin Biosciences raised a $330 million Series B led by TCG Crossover and ARCH Venture Partners to advance its pipeline of ophthalmic therapies, one of the largest biotech rounds of the period. The deal is a reminder that even amid AI's dominance of headlines and capital, large therapeutic biotech rounds remain a major and resilient corner of venture funding.

Suggest a correction